COVID-era generic drug price changes: No news is good news

CMS has released their latest round of drug pricing data – another peek into the functionality of the prescription drug supply chain amid the COVID-19 pandemic. As we highlighted in the June and July NADAC reports, generic drug prices are weathering the pandemic storm. In fact, not only have the predictions of massive increases failed to come to fruition, but instead, generic drug prices are falling. This month continues that trend. Our latest report digs into the numbers using the latest NADAC drug pricing data from CMS.

Ben LinkAugust 25, 2020NADAC, Medicaid, Generic, COVID, sertraline, Zoloft, Pepcid, Famotidine, Norflex, Orphenadrine, Shortages, Ampyra, Dalfampridine, Suboxone, Buprenorphine-Naloxone, Abilify, Aripiprazole